Thermo Fisher Scientific Inc. (NYSE:TMO – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-six brokerages that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $654.05.
A number of equities research analysts recently commented on the company. Citigroup downgraded Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a report on Wednesday, September 9th. UBS Group upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and upped their target price for the company from $540.00 to $730.00 in a research report on Tuesday, September 8th. Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target on the stock. Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an “overweight” rating for the company. Finally, Stifel Nicolaus set a $650.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, August 5th.
Read Our Latest Research Report on TMO
Thermo Fisher Scientific Stock Performance
Shares of TMO stock opened at $690.22 on Wednesday. The business has a fifty day moving average of $637.32 and a 200 day moving average of $548.58. Thermo Fisher Scientific has a 1 year low of $435.27 and a 1 year high of $704.00. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a market capitalization of $255.20 billion, a price-to-earnings ratio of 37.13, a price-to-earnings-growth ratio of 2.89 and a beta of 0.87.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The company’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts expect that Thermo Fisher Scientific will post 25.13 earnings per share for the current year.
Thermo Fisher Scientific News Roundup
Here are the key news stories impacting Thermo Fisher Scientific this week:
- Positive Sentiment: Analysts expect third-quarter adjusted earnings of approximately $6.40 per share, with results likely to show whether Thermo Fisher’s growth is continuing into the second half of 2026. Thermo Fisher Scientific Q3 2026 Preview
- Positive Sentiment: Recent investor commentary cites strong operating results and a recovery in Thermo Fisher’s Life Sciences Solutions business, while academic and government research spending remain important sources of demand. Thermo Fisher Scientific Outperforms on Strong Results and Life Sciences Recovery Academic and Government Spending Powers Thermo Fisher
- Positive Sentiment: Thermo Fisher is positioned to benefit from growth in immuno-oncology diagnostics, a market forecast to reach $11.1 billion by 2030, although the opportunity is shared with competitors including Roche, Illumina and Agilent. Immuno-Oncology Diagnostics Market Forecast
- Neutral Sentiment: Analysts are also examining key metrics such as segment performance and margins for the September quarter; those details could determine whether the expected earnings growth is high quality. Analyst Projections for Thermo Fisher Key Metrics
- Negative Sentiment: Valuation concerns may be weighing on the shares. Thermo Fisher trades at a premium earnings multiple after a substantial advance and has reached a new 52-week high, prompting some analysts to maintain a cautious or “hold” view despite strong growth prospects. Thermo Fisher Strong Growth, Even Higher Stock Price
Insider Activity
In related news, VP Lisa Britt sold 11,440 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares in the company, valued at $9,064,366.08. The trade was a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Joseph Holmes sold 420 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 73,768 shares of company stock valued at $44,122,820 over the last quarter. Insiders own 0.33% of the company’s stock.
Hedge Funds Weigh In On Thermo Fisher Scientific
Several institutional investors and hedge funds have recently modified their holdings of the stock. James T. Borello RIA acquired a new stake in Thermo Fisher Scientific during the third quarter worth about $57,000. V Square Quantitative Management LLC boosted its holdings in Thermo Fisher Scientific by 2.2% in the 3rd quarter. V Square Quantitative Management LLC now owns 2,451 shares of the medical research company’s stock valued at $1,655,000 after purchasing an additional 53 shares during the last quarter. YANKCOM Partnership boosted its holdings in Thermo Fisher Scientific by 4.7% in the 3rd quarter. YANKCOM Partnership now owns 1,405 shares of the medical research company’s stock valued at $948,000 after purchasing an additional 63 shares during the last quarter. Fortitude Advisory Group L.L.C. grew its stake in shares of Thermo Fisher Scientific by 5.7% in the 3rd quarter. Fortitude Advisory Group L.L.C. now owns 1,091 shares of the medical research company’s stock valued at $736,000 after buying an additional 59 shares during the period. Finally, Community Financial Services Group LLC grew its stake in shares of Thermo Fisher Scientific by 13.9% in the 3rd quarter. Community Financial Services Group LLC now owns 927 shares of the medical research company’s stock valued at $605,000 after buying an additional 113 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.
Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.
Featured Stories
- Five stocks we like better than Thermo Fisher Scientific
- These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
- Meta Claims Frontier-Class AI Status With New Muse Wonder Models
- Berkshire Just Backed This Little-Known Stock—Should You Chase It?
- Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
